Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Phase 1
Active, not recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: AXT107 Low DoseDrug: AXT107 Mid DoseDrug: AXT107 High Dose
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- AsclepiX Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05859776
- Locations
- 🇺🇸
New England Retina Consultants, Springfield, Massachusetts, United States
🇺🇸The Retina Institue, Saint Louis, Missouri, United States
🇺🇸Asheville Eye Associates, Asheville, North Carolina, United States
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Phase 1
Terminated
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- Drug: AXT107 0.1 mgDrug: AXT107 0.5 mgDrug: AXT107 0.25 mg
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- AsclepiX Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04746963
- Locations
- 🇺🇸
AsclepiX Investigative Site, The Woodlands, Texas, United States
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
Phase 1
Terminated
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Drug: AXT107 0.25 mgDrug: AXT107 0.5 mgDrug: AXT107 0.1 mg
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- AsclepiX Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04697758
- Locations
- 🇺🇸
AsclepiX Investigative Site, The Woodlands, Texas, United States
News
No news found